Swedish Orphan Biovitrum

223,4 SEK +0,18 %

1 sijoittaja seuraa yhtiötä

www.sobi.com/en/investors

Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.

Liikevaihto

18,79 mrd.

EBIT %

20,29 %

P/E -luku

25,04

Osinkotuotto %

Tavoitehinta

Suositus

Päivitetty

NASDAQ Stockholm

SOBI

Päivän matalin / päivän korkein hinta

222,4 / 227 SEK

Markkina-arvo

79,03 mrd. SEK

Vaihto

129,33 milj. SEK

Vaihtomäärä, kappaletta

578 t.

Pörssikalenteri

Osavuosikatsaus

30.10.2023

Vuosikatsaus

08.02.2024

Suurimmat omistajat
Lähde: Millistream Market Data AB

Omistaja	Osuus	Ääniä
Investor	34,6 %	34,6 %
Morgan Stanley Smith Barney	9,9 %	9,9 %

Inderes Premium

Premium ei aktivoitu

Tämä sisältö on vain Inderes Premium -käyttäjille.

Kirjaudu sisään Lue lisää

Näytä Kaikki sisältötyypit

Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)

Pörssitiedote29.09.2023

Swedish Orphan Biovitrum

Pörssikalenteri

Suurimmat omistajatLähde: Millistream Market Data AB

Inderes Premium

Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB: Sobi publishes the final outcome of the rights issue

Swedish Orphan Biovitrum AB: Sobi publishes the preliminary outcome of the rights issue

Swedish Orphan Biovitrum AB: Sobi publishes prospectus regarding the rights issue

Swedish Orphan Biovitrum AB: Sobi resolves on a rights issue of approximately SEK 6,024 million

Swedish Orphan Biovitrum AB: Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB: Sobi intends to carry out a rights issue of approximately SEK 6,000 million and calls for an Extraordinary General Meeting to be held on 15 August 2023

Swedish Orphan Biovitrum AB: Sobi publishes Q2 2023 report: Growth and pipeline expansion

New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB: Late-breaking efanesoctocog alfa data presented at ISTH demonstrates highly effective bleed protection in children with severe haemophilia A with once-weekly dosing

Swedish Orphan Biovitrum AB: Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

Swedish Orphan Biovitrum AB: Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

Swedish Orphan Biovitrum AB: EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

Swedish Orphan Biovitrum AB: Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology

Swedish Orphan Biovitrum AB: Bulletin from Swedish Orphan Biovitrum (Sobi)'s Annual General Meeting (AGM)

Swedish Orphan Biovitrum AB: Sobi publishes Q1 2023 report: Continued solid progress

Swedish Orphan Biovitrum AB: Sobi to streamline nirsevimab contractual arrangements

Swedish Orphan Biovitrum AB: Sobi® publishes Annual and sustainability report for 2022

Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)

Suurimmat omistajat
Lähde: Millistream Market Data AB